The founding premise of Enara Bio was a forward-looking belief. As the T-cell engager field matured, they predicted a critical shortage of viable targets would emerge. By creating a platform to discover novel "dark antigens" from the non-coding genome, they positioned themselves to solve a problem before it became mainstream.

Instead of only seeking disease-causing genes, Regeneron's primary strategy is to find rare protective mutations in individuals they call "superhumans." These people, naturally protected from diseases like heart attacks, provide a validated blueprint for new drugs. The company has already found over 50 such protective factors.

The discovery-based model of finding highly impactful single targets like HER2 or PD-1 is becoming unsustainable as the low-hanging fruit is picked. The field must shift toward an engineering-first approach, designing complex, multi-functional therapeutics to achieve specific clinical objectives, much like high-tech fields.

Pharmaceutical companies like Pfizer have vast amounts of human genetic data (GWAS hits) linked to diseases but struggle to determine which are viable drug targets. Gordian's high-throughput in vivo screening directly tests the causal effects of hundreds of these targets, rapidly identifying the most promising candidates.

Regeneron's Genetics Center is a key competitive advantage, functioning as a discovery engine for new drug targets. By sequencing millions of patient genomes and linking them to health records, it allows Regeneron to identify novel genetic variants associated with diseases, feeding its antibody development pipeline with proprietary targets.

A-muto's CEO argues that shaving months off discovery isn't the real prize. The massive cost in drug development comes from late-stage clinical failures. By selecting highly disease-specific targets upfront, their platform aims to reduce the high attrition rate in clinical trials, which is the true driver of cost and delay.

Regeneron's genetics engine created so many new targets that it revealed a strategic weakness: two-thirds were intracellular and untreatable with its world-class antibody platform. This success forced the company to "reinvent itself" and invest heavily in new modalities like sRNA and gene therapy to capitalize on its own discoveries.

Beyond accelerating timelines, AI's real value lies in its ability to design molecules for targets previously considered 'hard-to-drug.' These models operate on different principles than traditional lab methods and are indifferent to historical challenges, opening up entirely new therapeutic possibilities.

Regeneron systematically expands the market for its drugs through "indication expansion." By identifying people in its database with a natural loss-of-function variant for a drug's target, they can scan thousands of diseases to see what other conditions these people are protected from, revealing new therapeutic opportunities.